433-07-8

Basic information

• Product Name: 2-fluoropropane-1,3-diyl bis(4-methylbenzenesulfonate)
• Synonyms: 2-fluoropropane-1,3-diyl bis(4-methylbenzenesulfonate)
• CAS NO: 433-07-8
• Molecular Weight: 402.465
• Mol File: 433-07-8.mol

Chemical Properties

• CAS DataBase Reference: 2-fluoropropane-1,3-diyl bis(4-methylbenzenesulfonate)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-fluoropropane-1,3-diyl bis(4-methylbenzenesulfonate)(433-07-8)
• EPA Substance Registry System: 2-fluoropropane-1,3-diyl bis(4-methylbenzenesulfonate)(433-07-8)

Safety Data

• Hazardous Substances Data: 433-07-8(Hazardous Substances Data)

Upstream product

• 453-09-8 2-fluoropropane-1,3-diol 
• 98-59-9 p-toluenesulfonyl chloride 
• 1786-38-5 1,3-dibromo-2-fluoropropane 
• 16836-95-6 silver(I) 4-methylbenzenesulfonate 
• 4124-41-8 p-toluenesulfonylanhydride 
• 40879-42-3 2-hydroxypropane-1,3-diyl bis(4-methylbenzenesulfonate) 

Downstream Products

• 39198-40-8 Toluene-4-sulfonic acid 2-fluoro-hex-5-enyl ester 
• 1236211-62-3 5,5‘-(2-fluoropropane-1,3-diyl)bis-(oxy)bis-(4-oxo-4H-chromene-2-carboxylic acid) 

Relevant articles and documents

The intramolecular β-fluorine...ammonium interaction in 4- and 8-membered rings

The structures of 3-fluoroazetidinium hydrochloride and 3-fluoro-1,5-diazacyclooctane hydrobromide are explored both by X-ray diffraction analysis and DFT calculations, and the conformations of these molecules are shown to be significantly influenced by t

CROMOLYN ESTERS AND USES THEREOF

Described herein are compounds and methods of treating or imaging a disease or disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amoun

MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES

Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromol

NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

6,7-DIHYDRO-5H-PYRAZOLO[5,1-B][1,3]OXAZINE-2-CARBOXAMIDE COMPOUNDS

The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R 3, and R 4are as defined herein. The invention is also di

CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT

Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula (I), o

INHIBITORS OF AKT ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.